This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartz, G. G. Articles by Torti, F. M. Search for Related Content PubMed PubMed Citation Articles by Schwartz, G. G. Articles by Torti, F. M.

Phase I/II Study of 19-nor-1-25-Dihydroxyvitamin D₂ (Paricalcitol) in Advanced, Androgen-Insensitive Prostate Cancer

Authors' Affiliations: Departments of ¹ Cancer Biology, ² Urology, and ³ Hematology/Oncology; ⁴ Section on Biostatistics, Department of Public Health Sciences; and ⁵ Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina; and ⁶ Northwest Georgia Oncology Centers, Douglasville, Georgia

Requests for reprints: Frank M. Torti, Comprehensive Cancer Center, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157. Phone: 336-716-7971; Fax: 336-716-0293; E-mail: ftorti{at}wfubmc.edu.

Purpose: We assessed the safety and efficacy of the vitamin D analogue, 19-nor-1-25-dihydroxyvitamin D₂ (paricalcitol), in patients with androgen-independent prostate cancer.

Experimental Design: Patients received paricalcitol i.v. three times per week on an escalating dose of 5 to 25 µg (3-15 µg/m²). The primary end point was prostate-specific antigen (PSA) response. Secondary end points were characterization of toxicity in this population, changes in serum parathyroid hormone (PTH), and survival.

Results: A total of 18 patients were enrolled. No patient showed a sustained 50% drop in serum PSA, despite several large declines in PSA (e.g., 1,300 ng/mL). Paricalcitol was well tolerated. One instance of significant hypercalcemia, a serum calcium of 14.3 mg/dL, was observed at the highest dose (25 µg). At entry into the study, seven (41%) of the patients had elevated serum levels of PTH, which were significantly reduced by paricalcitol. Higher levels of serum PTH at study entry were significantly and negatively associated with survival (P < 0.01).

Conclusion: No objective responses were seen in the primary end point. However, elevated serum levels of PTH, a common feature of advanced prostate cancer, were reduced by paricalcitol. Because elevated PTH is associated with increased cardiovascular and skeletal morbidity, including an increased risk for pathologic fracture, further evaluation of paricalcitol in the reduction of skeletal morbidity in advanced prostate cancer is warranted.

This article has been cited by other articles:

				C. M. Ulrich and R. S. Holmes Shedding Light on Colorectal Cancer Prognosis: Vitamin D and Beyond J. Clin. Oncol., June 20, 2008; 26(18): 2937 - 2939. [Full Text] [PDF]

				G. G. Schwartz Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 478 - 483. [Abstract] [Full Text] [PDF]

				N. Urushino, S. Nakabayashi, M. A. Arai, A. Kittaka, T. C. Chen, K. Yamamoto, K. Hayashi, S. Kato, M. Ohta, M. Kamakura, et al. Kinetic Studies of 25-Hydroxy-19-nor-vitamin D3 and 1{alpha},25-Dihydroxy-19-nor-vitamin D3 Hydroxylation by CYP27B1 and CYP24A1 Drug Metab. Dispos., September 1, 2007; 35(9): 1482 - 1488. [Abstract] [Full Text] [PDF]

				W. Banach-Petrosky, X. Ouyang, H. Gao, K. Nader, Y. Ji, N. Suh, R. S. DiPaola, and C. Abate-Shen Vitamin d inhibits the formation of prostatic intraepithelial neoplasia in nkx3.1; pten mutant mice. Clin. Cancer Res., October 1, 2006; 12(19): 5895 - 5901. [Abstract] [Full Text] [PDF]

				J. Liao, A. Schneider, N. S. Datta, and L. K. McCauley Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res., September 15, 2006; 66(18): 9065 - 9073. [Abstract] [Full Text] [PDF]

				G. G. Schwartz and W. J. Blot Vitamin d status and cancer incidence and mortality: something new under the sun. J Natl Cancer Inst, April 5, 2006; 98(7): 428 - 430. [Full Text] [PDF]

				S. Masuda and G. Jones Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther., April 1, 2006; 5(4): 797 - 808. [Abstract] [Full Text] [PDF]